亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Dissecting the Tumor Microenvironment to Predict Immunotherapy Response in Hepatocellular Cancer

阿替唑单抗 贝伐单抗 免疫疗法 肿瘤微环境 肝细胞癌 医学 癌症 肿瘤科 无容量 内科学 化疗
作者
Antonio D’Alessio,David James Pinato
出处
期刊:Gastroenterology [Elsevier BV]
卷期号:163 (6): 1712-1713 被引量:7
标识
DOI:10.1053/j.gastro.2022.08.024
摘要

Zhu AX, Abbas AR, de Galarreta MR, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med 2022;28:1599–1611. Immunotherapy development for hepatocellular carcinoma (HCC) faces unique challenges owing to the peculiarities of this cancer type, which arises on a chronically active yet dysfunctional immune background. Biomarkers with an established predictive role in other inflammation-mediated tumors, such as programmed-death ligand 1 expression or tumor mutational burden have failed to identify responders to immune checkpoint inhibitors in HCC, leaving the provision of immunotherapy in routine practice and the development of novel regimens completely unsupported by reproducible biologic correlates. Recent studies demonstrate that combination immuno- and anti-angiogenesis therapy (atezolizumab plus bevacizumab) achieve an unprecedented survival advantage in patients with unresectable HCC, lending a median overall survival of 19.2 months in patients whose prognosis was historically limited to <6 months. However, measurable responses were achieved in a minority of patients and treatment-related toxicity can be life threatening. Therefore, the study from Zhu et al provides a significant step forward in addressing the acute unmet need for predictive biomarkers of response to immunotherapy in HCC. By presenting a comprehensive series of integrated analyses on patient samples collected within the phase Ib GO30140 trial and the phase III IMbrave150 trial, the authors provide practice-informing data demonstrating that the existence of preexisting T-cell immunity is a key phenotypic characteristic that correlates with response to atezolizumab plus bevacizumab. By integrating the results of whole genome RNA sequencing with multiplex immunohistochemistry of pre-treatment tissue samples, the authors demonstrate that an imbalance of the tumor microenvironment (TME) favoring the enrichment of the effector T-cell response over immunosuppressive regulatory T cells identifies patients who achieve significantly improved survival from the combination. To complement translational data, the authors provide further mechanistic insight into the synergistic role of anti-vascular endothelial growth factor and programmed death-1 pathway blockade in murine models, documenting how the addition of bevacizumab can enhance atezolizumab-mediated remodeling of immune-suppressive signals within the TME. Taken together, these findings ascribe HCC as an oncological diagnosis in which the presence of spontaneous immunogenicity is key to immunotherapy efficacy. Although histopathologic assessment confirms itself as an irreplaceable source of predictive information, TME immunogenicity is a function of density, functional polarization, and distribution of the infiltrate. The heterogeneity of the HCC TME and need for more readily applicable biomarkers than complex high-throughput transcriptomics remains a challenge for immediate clinical translation. Despite these limitations, the study by Zhu et al establishes a rationale to prospectively assess the TME as source of clinical stratification in trial participants. The interest of this approach extends beyond prediction of response to existing therapies. Identifying nonimmunogenic HCC, for instance, can lead to targeted testing of novel combinations modulating prognostically adverse traits such as regulatory T-cell infiltration, therefore broadening the reach of effective cancer immunotherapy to a wider proportion of patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
缥缈的鸡翅完成签到,获得积分10
1秒前
leafy189完成签到,获得积分10
3秒前
ASZI完成签到 ,获得积分10
4秒前
5秒前
愉快的惋庭完成签到,获得积分10
8秒前
8秒前
KKIII完成签到,获得积分10
10秒前
ldxghh发布了新的文献求助10
10秒前
11秒前
梦梦的应助被盖世小么得采纳,获得10
11秒前
完美世界的应助被dd采纳,获得10
16秒前
18秒前
真实的曼柔完成签到 ,获得积分10
19秒前
21秒前
22秒前
26秒前
26秒前
悦兮的应助被科研通管家采纳,获得10
26秒前
花痴的向卉完成签到,获得积分10
27秒前
朴素半烟完成签到 ,获得积分10
27秒前
打打的应助被科研通管家采纳,获得10
27秒前
27秒前
KKIII发布了新的文献求助10
30秒前
2589完成签到,获得积分10
30秒前
淡然的冰淇淋完成签到 ,获得积分10
38秒前
坦率的邑完成签到 ,获得积分10
46秒前
50秒前
冷酷的祥完成签到,获得积分10
50秒前
睡觉大王__完成签到,获得积分10
52秒前
科研小白发布了新的文献求助10
53秒前
obedVL完成签到,获得积分10
54秒前
风趣含双发布了新的文献求助10
1分钟前
背后寒烟完成签到 ,获得积分10
1分钟前
Yh完成签到,获得积分10
1分钟前
从容棉花糖完成签到,获得积分10
1分钟前
cloud完成签到 ,获得积分10
1分钟前
Yh发布了新的文献求助10
1分钟前
敬业乐群完成签到,获得积分10
1分钟前
陈龙完成签到,获得积分10
1分钟前
aa完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172954
求助须知:如何正确求助?哪些是违规求助? 9565447
关于积分的说明 21780029
捐赠科研通 7764817
什么是DOI,文献DOI怎么找? 3431496
关于科研通互助平台的介绍 2555519
邀请新用户注册赠送积分活动 2476571